Img header logo

ESG Data

アンカーリンク用

Regarding the data for FY2019 marked with ★, we have received independent assurance in our CSR Report 2020 (PDF version) so as to bolster the reliability of the information.

ONO PHARMACEUTICAL CO.,LTD., ONO PHARMACEUTICAL CO.,LTD., system

Governance Data

Corporate Governance
Category Item Scope Unit FY2016 FY2017 FY2018 FY2019
Corporate Governance Structure Board
structure		 Directors (Total) Non-consolidated Persons 7 7 8 8
Independent outside directors Non-consolidated Persons 2 2 3 3
Female directors Non-consolidated Persons 0 0 0 0
Board of Auditors structure Auditors (Total) Non-consolidated Persons 4 4 4 4
Independent outside auditors Non-consolidated Persons 2 2 2 2
Female auditors Non-consolidated Persons 1 1 1 1
Director Remuneration Total Non-consolidated Million
yen		 345 336 360 368
President, Representative Director, and Chief Executive Officer Non-consolidated Million
yen		 - - 114 116
Auditor Remuneration Total Non-consolidated Million
yen		 71 76 77 78
Number of Board of Directors meetings Non-consolidated Times 15 13 13 13
Number of Board of Auditors meetings Non-consolidated Times 13 13 14 14
Board attendance rate（directors） Non-consolidated % - 100.0 100.0 100.0
Board attendance rate（auditors） Non-consolidated % - - 100.0 92.3*1
Compliance Number of bribery cases Non-consolidated Cases 0 0 0 0
Number of disciplinary actions Non-consolidated Cases - - 5 9
Number of facilitation payments Non-consolidated Cases 0 0 0 0
Compliance training attendance rate Non-consolidated % - - 100 100
Number of reports  Non-consolidated Cases - - 44 68
Number of compliance violations Non-consolidated Cases - - 5 9
  • The attendance rate of Audit & Supervisory Board Members excluding the Audit & Supervisory Board Member who resigned due to illness on March 27, 2020 was 100%.
ONO PHARMACEUTICAL CO.,LTD., ONO PHARMACEUTICAL CO.,LTD., system

Social Data

Innovative Pharmaceutical Products
Category Item Scope Unit FY2016 FY2017 FY2018 FY2019
Research Development R&D expenses Non-consolidated Million
yen		 57,506 68,821 　70,008 66,497
Ratio of R&D expenses to net sales Non-consolidated % 23.5 26.3 　24.3 22.7
Human Resources and Human Rights
Category Item Scope Unit FY2016 FY2017 FY2018 FY2019
Provision of Growth Opportunities Company-wide
joint
training
implementation
status		 Workshop for deep understanding our mission statement Non-consolidated Participants
× hours		 - 943 317 317
Non-consolidated Participants - 145 56 54
On-site training at medical institutions Non-consolidated Participants
× hours		 5,293 231 681 822
Non-consolidated Participants 1,093 28 127 105
Patient associations’ lecture meetings/Virtual Reality (VR) patient experience Non-consolidated Participants
× hours		 - - - 2,743
Non-consolidated Participants - - - 1,704
Special training program for global business Non-consolidated Participants
× hours		 1,388 2,704 3,341 3,634
Non-consolidated Participants 30 39 52 61
Speaking skill of English training program Non-consolidated Participants
× hours		 - 11,988 19,215 15,912
Non-consolidated Participants - 111 260 216
Orientation for newly hired employees/
Follow-up training for newly hired employees		 Non-consolidated Participants
× hours		 - 9,408 7,682 6,253
Non-consolidated Participants - 98 86 70
Third-year employee training/
Fifth-year employee training		 Non-consolidated Participants
× hours		 - 3,040 1,667 2,148
Non-consolidated Participants - 190 164 173
Training for individual contributors promoted to the highest level/
Training for new core employees/
Training for new managers/
Manager training		 Non-consolidated Participants
× hours		 - 11,968 11,653 4,400
Non-consolidated Participants - 748 1,027 357
Self-development learning (Correspondence courses/Online foreign language conversation/ support for qualification tests) Non-consolidated Participants 223 324 378 532
Elective and Voluntary training Non-consolidated Participants
× hours		 - 2,604 2,513 5,963
Non-consolidated Participants - 217 231 681
Diversity management training Non-consolidated Participants
× hours		 - 108 1,529 32
Non-consolidated Participants - 27 734 48
Career planning training Non-consolidated Participants
× hours		 - 1,362 426 345
Non-consolidated Participants - 190 142 115
Coaching training Non-consolidated Participants
× hours		 - 1,950 992 858
Non-consolidated Participants - 78 37 32
Annual training hours per employee Non-consolidated Hours - - 35.5 30.7
Classification by training category General capability development Consolidated Participants
× hours		 - - - 39,189
Participants - - - 16,194
Professional capability development Consolidated Participants
× hours		 - - - 57,226
Participants - - - 11,012
Compliance training Consolidated Participants
× hours		 - - - 6,885
Participants - - - 13,999
Promoting active participation of persons with disabilities/mid-career employment Employment of persons with disabilities Non-consolidated % 2.30 2.24 2.28 2.20
Mid-career employment（Cumulative） Non-consolidated Persons 322 380 440 446
Employee composition Male ratio of new graduates Non-consolidated % 57 66 51 66
Female ratio of new graduates Non-consolidated % 43 34 49 34
Employee（Male） Non-consolidated Persons 2,358 2,629 2,682 2,676
Employee（Female） Non-consolidated Persons 524 570 602 611
Employee（total） Non-consolidated Persons 3,062 3,199 3,284 3,287
Contract workers ratio Non-consolidated % - 0.3 0.1 0.1
Temporary staff ratio Non-consolidated % - 8.8 8.9 8.0
Average age (male) Non-consolidated Years old 41.1 42.1 42.6 42.7
Average age (female) Non-consolidated Years old 37.1 37.9 38.0 37.9
Average age (total) Non-consolidated Years old 40.4 41.4 41.8 41.9
Average consecutive years of employment（male） Non-consolidated Years 15.9 16.0 16.3 15.9
Average consecutive years of employment（female） Non-consolidated Years 12.3 11.8 12.0 11.1
Average consecutive years of employment（total） Non-consolidated Years 15.3 15.3 15.5 15.0
Employee information Average annual salary Non-consolidated JPY 10,000 897 906 917 928
Collective bargaining rights holding rate Non-consolidated % - - - 97.3
Labor union participation rate Non-consolidated % 68.6 66.8 65.1 60.8
Employee satisfaction rate (male) Non-consolidated % - - 68 -
Employee satisfaction rate (female) Non-consolidated % - - 57 -
Employee satisfaction rate (all) Non-consolidated % 62 - 66 -
Female manager rate Non-consolidated % 3.4 3.9 4.0 4.6
Turnover and retention rate Retention rate after 3 years（male） Non-consolidated % 93.1 98.4 96.1 95.4
Retention rate after 3 years（female） Non-consolidated % 85.4 96.9 100.0 90.9
Retention rate after 3 years（total） Non-consolidated % 89.9 97.8 97.8 93.9
Full-time employee turnover rate（voluntary resignation） Non-consolidated % 1.0 1.3 1.5 1.6
Full-time employee turnover rate（Mandatory retirement, etc.） Non-consolidated % 0.9 0.7 0.6 0.2
Full-time employee turnover rate（total） Non-consolidated % 1.9 2.0 2.1 1.8
Safety and Health
Category Item Scope Unit FY2016 FY2017 FY2018 FY2019
Enhancing cultivation of employee-friendly workplaces Overtime hours Non-consolidated ％
compared
to
previous
year		 N/A ▽0.5％ ▽5.7%（compared to FY2014） ▽14.5%（compared to FY2014）
Percentage of paid vacation taken Non-consolidated ％
compared
to
previous
year		 N/A △6.4％ △17.2％（compared to FY2014） △24.7％（compared to FY2014）
Occupational
injuries		 Number
of
lost-time
injuries
★		 All Japanese operation sites
（Employees）*2		 Incidents 1 1 1 0
All Japanese operation sites
（Temporary employees）*6		 Incidents - - - 1
Lost-time injury frequency rate*3★ All Japanese operation sites
（Employees）*2		 - 0.16 0.16 0.15 0.00
All Japanese operation sites
（Temporary employees）*6		 - - - - 2.09
Number of occupational illnesses*4★ All Japanese operation sites
（Employees）*6		 Incidents - - - 0
Occupational illness frequency rate*5★ All Japanese operation sites
（Employees）*6		 - - - - 0.00
Supporting disease prevention, early detection and early treatment Medical checkups received Non-consolidated % - 99.1 99.4 99.7
Cancer screening rate Stomach cancer screening Non-consolidated % - 97.2 97.3 97.7
Lung cancer screening Non-consolidated % - 99.3 99.7 99.9
Colorectal cancer screening Non-consolidated % - 93.9 93.6 95.8
Breast cancer screening Non-consolidated % - 90.0 88.3 86.7
Cervical cancer Non-consolidated % - 43.4 42.3 47.3
Mental health Stress checks received Non-consolidated % - 95.1 99.4 99.8
Health promotion Number of participants in walking campaign Employees Non-consolidated Persons 887 1,088 1,169 1,450
Family Non-consolidated Persons 256 472 771 987
Temporary staff, etc. Non-consolidated Persons 68 99 90 124
Walking campaign total employee participation rate Non-consolidated % - 34 35 44
  • Scope before FY 2016: Domestic plants and research institutes
  • Lost-time injury frequency rate = (number of lost-time injuries / total number of actual working hours) x 1,000,000
  • Occupational illness: Diseases on the occupational disease list of the Ministry of Health, Labor and Welfare, excluding those reported as occupational illnesses.
  • Occupational illness frequency rate = (number of occupational illnesses / total number of actual working hours) x 1,000,000
  • The data on the number of lost-time injuries and the lost-time injury frequency rate for temporary employees, and the data on the number of occupational illnesses and the occupational illness frequency rate, are subject to disclosure from FY2019.
ONO PHARMACEUTICAL CO.,LTD., ONO PHARMACEUTICAL CO.,LTD., system

Environmental Data

Energy Saving and Global Warming PreventionThe scope of environmental data is non-consolidated basis
Category Item Scope Unit FY2016 FY2017 FY2018 FY2019
GHG emissions Energy-derived GHG  emissions（Location-basis）★ Production and research sites 10,000
t-CO2		 2.06 2.07 2.17 2.37
Headquarters and other Sites in Japan（including tenant locations） 10,000
t-CO2		 0.17 0.17 0.18 0.17
Total 10,000
t-CO2		 2.23 2.24 2.35 2.54
Energy-
derived GHG
emissions
scope
breakdown
（Location-
basis）★		 Scope 1 All operation sites 10,000
t-CO2		 0.85 0.85 0.90 0.97
Scope 2 All operation sites 10,000
t-CO2		 1.38 1.39 1.45 1.57
GHG emissions (Market-basis)★ Production and research sites 10,000
t-CO2		 2.73 2.72 2.61 2.52
Headquarters and other Sites in Japan（including tenant locations） 10,000
t-CO2		 0.26 0.26 0.24 0.21
Total 10,000
t-CO2		 2.99 2.98 2.85 2.73
GHG
emissions
scope
breakdown
(Market-
basis)★		 Scope 1
(Breakdown by GHG type）		 Energy-derived CO2 All operation sites 10,000
t-CO2		 0.85 0.85 0.90 0.98
Hydrofluorocarbon (HFC) - 0.02 0.05 0.04
Total 0.85 0.87 0.95 1.02
Scope 2 All operation sites 10,000
t-CO2		 2.14 2.11 1.90 1.71
GHG emissions in the value chain (Scope3)★ Cat1 Purchased goods and services*7 All operation sites 10,000
t-CO2		 9.71 0.85 0.81 -*8
Cat2 Capital goods 10,000
t-CO2		 2.70 5.26 　6.04 2.69
Cat3 Fuel- and energy-related activities not included in scope 1 or scope 2 10,000
t-CO2		 0.15 0.15 　0.15 0.28
Cat4 Upstream transportation and distribution 10,000
t-CO2		 0.01 0.01 　0.01 0.01
Cat5 Waste generated in operations 10,000
t-CO2		 0.03 0.03 　0.03 0.03
Cat6 Business travel 10,000
t-CO2		 0.22 0.25 　0.23 0.40
Cat7 Employee commuting 10,000
t-CO2		 0.03 0.04 　0.04 0.05
Cat8 Upstream leased assets 10,000
t-CO2		 0.35 0.35 　0.33 0.29
Cat9 Downstream transportation and distribution 10,000
t-CO2		 0.62 0.53 0.53 -*8
Cat10 Processing of sold products 10,000
t-CO2		 Not relevant Not relevant Not relevant Not relevant
Cat11 Use of sold products 10,000
t-CO2		 Not relevant Not relevant Not relevant Not relevant
Cat12 End-of-life treatment of sold products 10,000
t-CO2		 0.02 0.01 0.02 0.02
Cat13 Downstream leased assets 10,000
t-CO2		 0.03 0.03 0.03 0.03
Cat14 Franchises 10,000
t-CO2		 Not relevant Not relevant Not relevant Not relevant
Cat15 Investments 10,000
t-CO2		 Not relevant Not relevant Not relevant Not relevant
Total 10,000
t-CO2		 13.87 7.51 8.22 -*8
Energy consumption Energy consumption★ Production and research sites 10,000
GJ		 52.72 52.65 55.42 60.80
Headquarters and other Japan offices/sites（including tenant locations） 10,000
GJ		 5.04 5.09 5.13 4.95
Total 10,000
GJ		 57.76 57.74 60.55 65.75
Renewable
energy
amount		 Solar power generation
(by private power generation)		 All operation sites MWh 53.96 55.29 64.97 63.03
Solar power generation
(by purchase)		 MWh - - - 2,427
hydroelectric generation MWh - - - 1,278
Biomass power generation (by purchase) MWh - - 2,900 2,460.90
  • Calculation method of category 1 in Scope 3, “Purchased goods and services”, was changed from FY2017.
    FY2016 and previous fiscal years: Purchase cost of raw materials, materials, etc., multiplied by emission factor stated in “Emission Factor Database on Accounting for Greenhouse Gas Emissions throughout the Supply Chain (ver. 2 .4),” published by the Ministry of the Environment, Government of Japan.
    Since FY2017: CO2 emissions(Scope 1,2) volume of our raw materials and materials suppliers (accounting for 80% or more of our raw materials or materials purchase costs) multiplied by the ratio of the sales to ONO out of the total sales of the supplier. Ratios for other business suppliers are assumed to follow the same trend as for major suppliers, and are calculated using the ratio of CO2 emissions to the transaction amount at major suppliers.
  • Because our major business partners had not published their CSR reports at the time of calculation.
Efforts Made for Reducing Water Use
Category Item Scope Unit FY2016 FY2017 FY2018 FY2019
Water intake★ Water intake per site (Basin) Fujiyama Plant/Joto factory (current Joto Pharmaceutical Product Development Center)/MinaseResearch Institute/Fukui Research Institute/Tsukuba Research Institute/Headquarters, other Japan offices and sites 10,000
m3		 29.84 32.56 34.80 29.67
Fuji river Fujiyama Plant 10,000
m3		 19.57 20.56 24.02 18.50
Yodo river Joto factory (current Joto Pharmaceutical Product Development Center) 10,000
m3		 0.72 0.55 0.60 0.51
Yodo river Minase Research Institute 10,000
m3		 4.52 5.13 4.12 3.91
Kuzuryu river Fukui Research Institute 10,000
m3		 3.94 3.87 3.13 2.73
Lake Kasumigaura Tsukuba Research Institute 10,000
m3		 1.09 0.81 0.60 0.71
Fushino river Yamaguchi Plant 10,000
m3		 - - 0.82 1.81
Basins of major offices*9 Headquarters and other Japan offices/sites (including some tenant locations) 10,000
m3		 - 1.64 1.51 1.50
Wastewater★ Wastewater site (destination) Fujiyama Plant/Joto factory (current Joto Pharmaceutical Product Development Center)/MinaseResearch Institute/Fukui Research Institute/Tsukuba Research Institute/Headquarters, other Japan offices and sites 10,000
m3		 19.97 23.51 25.99 23.52
River Fujiyama Plant 10,000
m3		 12.89 14.86 17.84 14.51
Sewer Joto factory (current Joto Pharmaceutical Product Development Center) 10,000
m3		 0.72 0.55 0.60 0.51
Sewer Minase Research Institute 10,000
m3		 4.52 5.13 4.12 3.91
Sewer Fukui Research Institute 10,000
m3		 0.75 0.52 0.50 0.57
Sewer Tsukuba Research Institute 10,000
m3		 1.09 0.81 0.60 0.71
River Yamaguchi Plant 10,000
m3		 - - 0.82 1.81
Sewer Headquarters and other Japan offices/sites (including some tenant locations) 10,000
m3		 - 1.64 1.51 1.50
Percentage of reused water 　 Production and research sites % - 5.90 4.60 5.51
  • Basins of major offices: Toyohira River, Okura River, Arakawa River, Sakawa River, Kiso River, Lake Biwa, Yodo River, Ota River, Yoshino River, Naka River
Waste Management, and Recycling Containers and Product Packaging
Category Item Scope Unit FY2016 FY2017 FY2018 FY2019
Waste Industrial
waste★		 Waste generated Production and research sites t 534.6 719.1 446.4 430.8
Specially management industrial waste Production and research sites t 138.1 137.0 145.6 161.9
final landfill disposal Production and research sites t 0.7 7.4 0.4 0.2
final landfill disposal rate Production and research sites % 0.13 1.02 0.09 0.05
final landfill disposal
(Non-industrial waste is included)		 Production and research sites t 10.66 18.04 9.35 6.75
Container and packaging usage Plastic Production and research sites t - 164.7 171.7 162.8
Paper Production and research sites t - 192.0 202.7 200.9
Glass (colorless) Production and research sites t - 0 0 0
Glass (brown) Production and research sites t - 0.3 0.3 0.3
Obligatory recycling amount Plastic Production and research sites t - 34.7 35.5 31.2
Paper Production and research sites t - 1.6 1.6 1.5
Glass (colorless) Production and research sites t - 0 0 0
Glass (brown) Production and research sites t - 0 0 0
Commissioning fee paid for recycling Production and research sites 1,000
yen		 - 1,723 1,650 1,546
PRTR substance Production and research sites t 10.94 11.79 9.76 11.34
Prevention of Air Pollution and Water Pollution
Category Item Scope Unit FY2016 FY2017 FY2018 FY2019
Emissions into the air SOx Production and research sites t 0.00 0.00 0.00 0.00
NOx Production and research sites t 13.80 7.812 8.38 8.10
Particulate matter Production and research sites t 0.42 0.34 0.28 0.33
PRTR substance Production and research sites t 0.20 0.36 0.25 0.15
Emissions into water Wastewater Production and research sites 10,000
m3		 19.97 21.87 24.48 22.02
BOD Production and research sites t 2.38 2.22 1.27 1.31
PRTR substance Production and research sites t 0.00 0.00 0.00 0.00
Management of Chemicals
Category Item Scope Unit FY2016 FY2017 FY2018 FY2019
PRTR substances Amount
handled by
the notified
facilities		 Acetonitrile Production and research sites t 8.29 8.98 7.19 8.51
Normal-hexane Production and research sites t 2.95 2.97 2.82 2.98
Total Production and research sites t 11.24 11.95 10.01 11.49
Dioxins Production and research sites mg-TEQ - - - -
Notified release（into the air） Acetonitrile Production and research sites t 0.20 0.36 0.25 0.15
Normal-hexane Production and research sites t 0.00 0.00 0.00 0.00
Total Production and research sites t 0.20 0.36 0.25 0.15
Dioxins Production and research sites mg-TEQ 0.27 0.00 - -
Notified release（into public waters） Acetonitrile Production and research sites t 0.00 0.00 0.00 0.00
Normal-hexane Production and research sites t 0.00 0.00 0.00 0.00
Total Production and research sites t 0.00 0.00 0.00 0.00
Dioxins Production and research sites mg-TEQ 0.00 0.00 0.00 0.00
Notified transfer（contained in waste） Acetonitrile Production and research sites t 8.09 8.82 6.94 8.36
Normal-hexane Production and research sites t 2.85 2.97 2.82 2.98
Total Production and research sites t 10.94 11.79 9.76 11.34
Dioxins Production and research sites mg-TEQ 16.75 0.00 - -
Notified transfer（Into public sewage） Acetonitrile Production and research sites t 0.00 0.00 0.00 0.00
Normal-hexane Production and research sites t 0.00 0.00 0.00 0.00
Total Production and research sites t 0.00 0.00 0.00 0.00
Dioxins Production and research sites mg-TEQ 0.00 0.00 - -
Notified release and transfer (total) Acetonitrile Production and research sites t 8.29 8.98 7.19 8.51
Normal-hexane Production and research sites t 2.95 2.97 2.82 2.98
Total Production and research sites t 11.24 11.95 10.01 11.49
Dioxins Production and research sites mg-TEQ 17.02 0.00 - -
PCB Joto factory (current Joto Pharmaceutical Product Development Center) Stored（Fluorescent lamp） Production and research sites Stand 552 552 552 0
Disposed Production and research sites Stand 6 6 6 558
Minase Research Institute Disposed Production and research sites Stand 2 2 2 2
Green Purchasing
Category Item Scope Unit FY2016 FY2017 FY2018 FY2019
Green Purchasing office supplies purchased All operation sites ％ 83 80 76 76
Environmental Management
Category Item Scope Unit FY2016 FY2017 FY2018 FY2019
Management Acquisition status of ISO14001 Production site site 100% 100% 100% 100%
  • * Production sites in operation are 100% ISO14001 certified.
Environmental Violations
Category Item Scope Unit FY2016 FY2017 FY2018 FY2019
Environmental Violations Violation cases (with fines of USD 10,000 or more) All operation sites Cases 0 0 0 0
ONO PHARMACEUTICAL CO.,LTD., ONO PHARMACEUTICAL CO.,LTD., system

Social Contribution Activities Data

Social Contribution Activities
Category Item Scope Unit FY2016 FY2017 FY2018 FY2019
Initiatives for medical advancement Osamu Hayaishi Memorial Award － Persons - 1 1 1
Recipients of theresearch grant － Persons 12 12 12 12
Recipients of theresearch scholarship grant（40 years old and below） － Persons 16 16 16 16
Recipients of the Osamu Hayaishi Memorial Scholarship for Study Abroad － Persons 8 8 8 8
ONO PHARMACEUTICAL CO.,LTD., ONO PHARMACEUTICAL CO.,LTD., system